On November 10, Regeneron Pharmaceuticals rose 3.03% in Regular Trading, with shares trading at $931.7551 and turnover reaching $295 million.
The move coincided with newly disclosed liver-targeted siRNA study results showing that a single subcutaneous dose reduced liver fat by 58% to 80% at week 36, with a dose-dependent effect, while the placebo group showed a 2.9% reduction.
Further details indicated that 93% of treated participants achieved at least a 30% reduction in liver fat, many patients returned to normal liver-fat levels, and ALT and AST markers also improved over time. The update followed recent strong third-quarter results, when revenue rose 36.3% year over year to $5.12 billion and non-GAAP diluted EPS reached $20.07, above consensus expectations.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments